Active Ingredient History
Carbidopa is a competitive inhibitor of aromatic L-amino acid decarboxylase that does not cross the blood-brain barrier, is routinely administered with levodopa (LD) for the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Current evidence indicates that symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson’s disease apparently because it does not cross the blood-brain barrier. However, levodopa, the metabolic precursor of dopamine, does cross the blood- brain barrier, and presumably is converted to dopamine in the brain. When levodopa is administered orally it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. For this reason, large doses of levodopa are required for adequate therapeutic effect and these may often be accompanied by nausea and other adverse reactions, some of which are attributable to dopamine formed in extracerebral tissues. Carbidopa inhibits decarboxylation of peripheral levodopa. Carbidopa has not been demonstrated to have any overt pharmacodynamic actions in the recommended doses. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Pain (Phase 4)
Albinism (Phase 2)
Albinism, Oculocutaneous (Phase 2)
Alcohol Drinking (Phase 4)
Amblyopia (Phase 3)
Amyotrophic Lateral Sclerosis (Phase 1)
Angelman Syndrome (Phase 1)
Anhedonia (Phase 4)
Aphasia, Broca (Phase 2/Phase 3)
Asthma (Phase 1)
Autonomic Nervous System Diseases (Phase 3)
Back Pain (Phase 2)
Baroreflex (Phase 2)
Brain Injuries, Traumatic (Early Phase 1)
Bunion (Phase 2)
Cocaine-Related Disorders (Phase 2/Phase 3)
Cognitive Dysfunction (Phase 4)
Consciousness Disorders (Early Phase 1)
Depression (Phase 4)
Depressive Disorder (Phase 4)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 2)
Diabetic Retinopathy (Early Phase 1)
Dopamine beta-Hydroxylase (Phase 3)
Dysautonomia, Familial (Phase 3)
Dyskinesias (Phase 4)
Dysthymic Disorder (Phase 4)
Fasting (Phase 1)
Fibromyalgia (Phase 2)
Gait (Phase 4)
Haloperidol (Phase 1)
Healthy Volunteers (Phase 1)
Hypertension (Phase 1)
Hypotension, Orthostatic (Phase 3)
Levodopa (Phase 2)
Lewy Body Disease (Phase 1)
Macula Lutea (Phase 2)
Macular Degeneration (Phase 2)
Motor Activity (Phase 3)
Motor Neuron Disease (Phase 1)
Multiple Sclerosis (Phase 2)
Multiple System Atrophy (Phase 1/Phase 2)
Optic Neuropathy, Ischemic (Phase 4)
Orthostatic Intolerance (Phase 3)
Pharmacokinetics (Phase 1)
Placebos (Phase 1)
Postural Orthostatic Tachycardia Syndrome (Phase 2/Phase 3)
Pure Autonomic Failure (Phase 1)
Retina (Phase 2)
Retinitis Pigmentosa (Phase 2)
Schizophrenia (Phase 2)
Smoking (Phase 1)
Spinal Cord Injuries (Phase 2/Phase 3)
Stress Disorders, Post-Traumatic (Phase 2)
Stroke (Phase 4)
Stroke Rehabilitation (Phase 3)
Toes (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
